These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20597611)

  • 21. Denosumab for the management of postmenopausal osteoporosis.
    Singer A; Grauer A
    Postgrad Med; 2010 Nov; 122(6):176-87. PubMed ID: 21084794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study shows that a new type of osteoporosis drug reduces fracture risk.
    Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553
    [No Abstract]   [Full Text] [Related]  

  • 25. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Denosumab, the rheumatologist's joker?].
    Bérengère AR
    Rev Med Suisse; 2009 Jan; 5(185):59-62. PubMed ID: 19216327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Denosumab for the treatment of osteoporosis and cancer-related conditions.
    Lewiecki EM; Bilezikian JP
    Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab in postmenopausal women with low bone mineral density.
    Schwartzman J; Yazici Y
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
    [No Abstract]   [Full Text] [Related]  

  • 32. Denosumab in postmenopausal women with low bone mineral density.
    Rifkin WD
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of RANKL: a new approach to the treatment of osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1097-100. PubMed ID: 16722819
    [No Abstract]   [Full Text] [Related]  

  • 34. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RANKL pathway and denosumab.
    Dore RK
    Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent insights into the biology of bone turnover.
    Riches PL; Ralston SH
    J R Coll Physicians Edinb; 2010 Mar; 40(1):66-9. PubMed ID: 21125043
    [No Abstract]   [Full Text] [Related]  

  • 37. The role and efficacy of denosumab in the treatment of osteoporosis: an update.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Mar; 10(2):205-17. PubMed ID: 21208140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.
    Bekker PJ; Holloway DL; Rasmussen AS; Murphy R; Martin SW; Leese PT; Holmes GB; Dunstan CR; DePaoli AM
    J Bone Miner Res; 2005 Dec; 20(12):2275-82. PubMed ID: 16432953
    [No Abstract]   [Full Text] [Related]  

  • 39. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
    [No Abstract]   [Full Text] [Related]  

  • 40. Denosumab (Prolia): A new option in the treatment of osteoporosis.
    Belavic JM
    Nurse Pract; 2011 Jan; 36(1):11-2. PubMed ID: 21173630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.